nodes	percent_of_prediction	percent_of_DWPC	metapath
Vildagliptin—DPP4—blood vessel—systemic scleroderma	0.0327	0.211	CbGeAlD
Vildagliptin—DPP9—tendon—systemic scleroderma	0.0302	0.194	CbGeAlD
Vildagliptin—DPP9—lung—systemic scleroderma	0.0265	0.171	CbGeAlD
Vildagliptin—DPP4—connective tissue—systemic scleroderma	0.0168	0.108	CbGeAlD
Vildagliptin—Blister—Captopril—systemic scleroderma	0.016	0.0189	CcSEcCtD
Vildagliptin—DPP4—smooth muscle tissue—systemic scleroderma	0.0153	0.0989	CbGeAlD
Vildagliptin—DPP4—digestive system—systemic scleroderma	0.0121	0.0781	CbGeAlD
Vildagliptin—DPP4—tendon—systemic scleroderma	0.0115	0.0743	CbGeAlD
Vildagliptin—DPP4—lung—systemic scleroderma	0.0101	0.0652	CbGeAlD
Vildagliptin—Gastrooesophageal reflux disease—Mycophenolic acid—systemic scleroderma	0.01	0.0119	CcSEcCtD
Vildagliptin—Dermatitis bullous—Captopril—systemic scleroderma	0.00876	0.0104	CcSEcCtD
Vildagliptin—Nasopharyngitis—Mometasone—systemic scleroderma	0.00852	0.0101	CcSEcCtD
Vildagliptin—Infestation—Pentoxifylline—systemic scleroderma	0.00851	0.0101	CcSEcCtD
Vildagliptin—Infestation NOS—Pentoxifylline—systemic scleroderma	0.00851	0.0101	CcSEcCtD
Vildagliptin—Hepatic function abnormal—Azathioprine—systemic scleroderma	0.00836	0.00989	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Pentoxifylline—systemic scleroderma	0.00805	0.00953	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Mometasone—systemic scleroderma	0.00765	0.00906	CcSEcCtD
Vildagliptin—Hepatitis—Pentoxifylline—systemic scleroderma	0.00764	0.00904	CcSEcCtD
Vildagliptin—Pancreatitis—Captopril—systemic scleroderma	0.00709	0.00839	CcSEcCtD
Vildagliptin—Dermatitis bullous—Mycophenolic acid—systemic scleroderma	0.00688	0.00815	CcSEcCtD
Vildagliptin—Hepatic function abnormal—Lisinopril—systemic scleroderma	0.00678	0.00803	CcSEcCtD
Vildagliptin—Hypoglycaemia—Mycophenolic acid—systemic scleroderma	0.00674	0.00798	CcSEcCtD
Vildagliptin—Flatulence—Pentoxifylline—systemic scleroderma	0.00655	0.00776	CcSEcCtD
Vildagliptin—Liver function test abnormal—Leflunomide—systemic scleroderma	0.00637	0.00754	CcSEcCtD
Vildagliptin—Tremor—Pentoxifylline—systemic scleroderma	0.00623	0.00738	CcSEcCtD
Vildagliptin—Pancreatitis—Azathioprine—systemic scleroderma	0.00619	0.00733	CcSEcCtD
Vildagliptin—Angioedema—Pentoxifylline—systemic scleroderma	0.00608	0.00719	CcSEcCtD
Vildagliptin—Liver function test abnormal—Mycophenolic acid—systemic scleroderma	0.00608	0.00719	CcSEcCtD
Vildagliptin—Hypoglycaemia—Lisinopril—systemic scleroderma	0.00607	0.00719	CcSEcCtD
Vildagliptin—Nasopharyngitis—Mycophenolic acid—systemic scleroderma	0.00588	0.00697	CcSEcCtD
Vildagliptin—Pancreatitis—Leflunomide—systemic scleroderma	0.00584	0.00692	CcSEcCtD
Vildagliptin—Hepatitis—Captopril—systemic scleroderma	0.00579	0.00685	CcSEcCtD
Vildagliptin—Infestation NOS—Azathioprine—systemic scleroderma	0.00563	0.00666	CcSEcCtD
Vildagliptin—Infestation—Azathioprine—systemic scleroderma	0.00563	0.00666	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.00562	0.00666	CcSEcCtD
Vildagliptin—Pancreatitis—Mycophenolic acid—systemic scleroderma	0.00558	0.0066	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Leflunomide—systemic scleroderma	0.00554	0.00656	CcSEcCtD
Vildagliptin—Dermatitis bullous—Mycophenolate mofetil—systemic scleroderma	0.00543	0.00643	CcSEcCtD
Vildagliptin—Oedema—Pentoxifylline—systemic scleroderma	0.00543	0.00642	CcSEcCtD
Vildagliptin—Infection—Pentoxifylline—systemic scleroderma	0.00539	0.00638	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Azathioprine—systemic scleroderma	0.00532	0.0063	CcSEcCtD
Vildagliptin—Hypoglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00532	0.0063	CcSEcCtD
Vildagliptin—Infestation NOS—Leflunomide—systemic scleroderma	0.00532	0.00629	CcSEcCtD
Vildagliptin—Infestation—Leflunomide—systemic scleroderma	0.00532	0.00629	CcSEcCtD
Vildagliptin—Nasopharyngitis—Lisinopril—systemic scleroderma	0.0053	0.00627	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Mycophenolic acid—systemic scleroderma	0.00529	0.00626	CcSEcCtD
Vildagliptin—Skin disorder—Pentoxifylline—systemic scleroderma	0.00527	0.00624	CcSEcCtD
Vildagliptin—Hyperhidrosis—Pentoxifylline—systemic scleroderma	0.00525	0.00621	CcSEcCtD
Vildagliptin—Angioedema—Mometasone—systemic scleroderma	0.00524	0.00621	CcSEcCtD
Vildagliptin—Weight increased—Mycophenolic acid—systemic scleroderma	0.00518	0.00613	CcSEcCtD
Vildagliptin—Infestation NOS—Mycophenolic acid—systemic scleroderma	0.00507	0.006	CcSEcCtD
Vildagliptin—Infestation—Mycophenolic acid—systemic scleroderma	0.00507	0.006	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Leflunomide—systemic scleroderma	0.00503	0.00595	CcSEcCtD
Vildagliptin—Pancreatitis—Lisinopril—systemic scleroderma	0.00502	0.00594	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Pentoxifylline—systemic scleroderma	0.00494	0.00585	CcSEcCtD
Vildagliptin—Arthralgia—Mometasone—systemic scleroderma	0.00489	0.00578	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Mycophenolic acid—systemic scleroderma	0.0048	0.00568	CcSEcCtD
Vildagliptin—Liver function test abnormal—Mycophenolate mofetil—systemic scleroderma	0.00479	0.00568	CcSEcCtD
Vildagliptin—Hepatitis—Leflunomide—systemic scleroderma	0.00477	0.00565	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Lisinopril—systemic scleroderma	0.00476	0.00564	CcSEcCtD
Vildagliptin—Oedema peripheral—Leflunomide—systemic scleroderma	0.0047	0.00556	CcSEcCtD
Vildagliptin—Connective tissue disorder—Leflunomide—systemic scleroderma	0.00469	0.00555	CcSEcCtD
Vildagliptin—Weight increased—Lisinopril—systemic scleroderma	0.00466	0.00552	CcSEcCtD
Vildagliptin—Infection—Mometasone—systemic scleroderma	0.00465	0.00551	CcSEcCtD
Vildagliptin—Constipation—Pentoxifylline—systemic scleroderma	0.00464	0.00549	CcSEcCtD
Vildagliptin—Skin exfoliation—Prednisone—systemic scleroderma	0.00463	0.00548	CcSEcCtD
Vildagliptin—Angioedema—Captopril—systemic scleroderma	0.00461	0.00545	CcSEcCtD
Vildagliptin—Hepatitis—Mycophenolic acid—systemic scleroderma	0.00455	0.00539	CcSEcCtD
Vildagliptin—Chills—Azathioprine—systemic scleroderma	0.00453	0.00537	CcSEcCtD
Vildagliptin—Oedema peripheral—Mycophenolic acid—systemic scleroderma	0.00448	0.00531	CcSEcCtD
Vildagliptin—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.00447	0.0053	CcSEcCtD
Vildagliptin—Pancreatitis—Mycophenolate mofetil—systemic scleroderma	0.0044	0.00521	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Lisinopril—systemic scleroderma	0.00432	0.00511	CcSEcCtD
Vildagliptin—Urticaria—Pentoxifylline—systemic scleroderma	0.00431	0.0051	CcSEcCtD
Vildagliptin—Arthralgia—Captopril—systemic scleroderma	0.00429	0.00508	CcSEcCtD
Vildagliptin—Chills—Leflunomide—systemic scleroderma	0.00428	0.00507	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.00427	0.00505	CcSEcCtD
Vildagliptin—Malnutrition—Leflunomide—systemic scleroderma	0.00415	0.00492	CcSEcCtD
Vildagliptin—Angiopathy—Mycophenolic acid—systemic scleroderma	0.00413	0.00489	CcSEcCtD
Vildagliptin—Hepatitis—Lisinopril—systemic scleroderma	0.0041	0.00485	CcSEcCtD
Vildagliptin—Flatulence—Leflunomide—systemic scleroderma	0.00409	0.00485	CcSEcCtD
Vildagliptin—Weight increased—Mycophenolate mofetil—systemic scleroderma	0.00408	0.00484	CcSEcCtD
Vildagliptin—Chills—Mycophenolic acid—systemic scleroderma	0.00408	0.00483	CcSEcCtD
Vildagliptin—Oedema peripheral—Lisinopril—systemic scleroderma	0.00404	0.00478	CcSEcCtD
Vildagliptin—Fatigue—Mometasone—systemic scleroderma	0.00404	0.00478	CcSEcCtD
Vildagliptin—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.004	0.00474	CcSEcCtD
Vildagliptin—Infestation—Mycophenolate mofetil—systemic scleroderma	0.004	0.00474	CcSEcCtD
Vildagliptin—Malnutrition—Mycophenolic acid—systemic scleroderma	0.00396	0.00469	CcSEcCtD
Vildagliptin—Flatulence—Mycophenolic acid—systemic scleroderma	0.0039	0.00462	CcSEcCtD
Vildagliptin—Asthenia—Pentoxifylline—systemic scleroderma	0.00389	0.00461	CcSEcCtD
Vildagliptin—Skin exfoliation—Methotrexate—systemic scleroderma	0.00387	0.00458	CcSEcCtD
Vildagliptin—Angioedema—Leflunomide—systemic scleroderma	0.0038	0.00449	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.00378	0.00448	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.00375	0.00444	CcSEcCtD
Vildagliptin—Arthralgia—Azathioprine—systemic scleroderma	0.00374	0.00443	CcSEcCtD
Vildagliptin—Angiopathy—Lisinopril—systemic scleroderma	0.00372	0.0044	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00372	0.0044	CcSEcCtD
Vildagliptin—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00371	0.0044	CcSEcCtD
Vildagliptin—Tremor—Mycophenolic acid—systemic scleroderma	0.00371	0.00439	CcSEcCtD
Vildagliptin—Chills—Lisinopril—systemic scleroderma	0.00368	0.00435	CcSEcCtD
Vildagliptin—Hepatitis—Mycophenolate mofetil—systemic scleroderma	0.00359	0.00425	CcSEcCtD
Vildagliptin—Dizziness—Pentoxifylline—systemic scleroderma	0.00359	0.00425	CcSEcCtD
Vildagliptin—Malnutrition—Lisinopril—systemic scleroderma	0.00357	0.00422	CcSEcCtD
Vildagliptin—Infection—Azathioprine—systemic scleroderma	0.00357	0.00422	CcSEcCtD
Vildagliptin—Fatigue—Captopril—systemic scleroderma	0.00355	0.0042	CcSEcCtD
Vildagliptin—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.00354	0.00419	CcSEcCtD
Vildagliptin—Arthralgia—Leflunomide—systemic scleroderma	0.00354	0.00419	CcSEcCtD
Vildagliptin—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.00353	0.00418	CcSEcCtD
Vildagliptin—Constipation—Captopril—systemic scleroderma	0.00352	0.00416	CcSEcCtD
Vildagliptin—Flatulence—Lisinopril—systemic scleroderma	0.00352	0.00416	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00351	0.00416	CcSEcCtD
Vildagliptin—Skin disorder—Azathioprine—systemic scleroderma	0.00349	0.00413	CcSEcCtD
Vildagliptin—Headache—Pentoxifylline—systemic scleroderma	0.0034	0.00402	CcSEcCtD
Vildagliptin—Arthralgia—Mycophenolic acid—systemic scleroderma	0.00337	0.00399	CcSEcCtD
Vildagliptin—Infection—Leflunomide—systemic scleroderma	0.00337	0.00399	CcSEcCtD
Vildagliptin—Asthenia—Mometasone—systemic scleroderma	0.00336	0.00398	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00335	0.00397	CcSEcCtD
Vildagliptin—Tremor—Lisinopril—systemic scleroderma	0.00334	0.00396	CcSEcCtD
Vildagliptin—Nervous system disorder—Leflunomide—systemic scleroderma	0.00332	0.00394	CcSEcCtD
Vildagliptin—Skin disorder—Leflunomide—systemic scleroderma	0.00329	0.0039	CcSEcCtD
Vildagliptin—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00328	0.00388	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00327	0.00387	CcSEcCtD
Vildagliptin—Angioedema—Lisinopril—systemic scleroderma	0.00326	0.00386	CcSEcCtD
Vildagliptin—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00326	0.00386	CcSEcCtD
Vildagliptin—Oedema—Mycophenolic acid—systemic scleroderma	0.00323	0.00383	CcSEcCtD
Vildagliptin—Nausea—Pentoxifylline—systemic scleroderma	0.00322	0.00382	CcSEcCtD
Vildagliptin—Chills—Mycophenolate mofetil—systemic scleroderma	0.00322	0.00382	CcSEcCtD
Vildagliptin—Infection—Mycophenolic acid—systemic scleroderma	0.00321	0.0038	CcSEcCtD
Vildagliptin—Diarrhoea—Mometasone—systemic scleroderma	0.0032	0.00379	CcSEcCtD
Vildagliptin—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00317	0.00375	CcSEcCtD
Vildagliptin—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00314	0.00372	CcSEcCtD
Vildagliptin—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00313	0.0037	CcSEcCtD
Vildagliptin—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00313	0.0037	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.0031	0.00367	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00309	0.00366	CcSEcCtD
Vildagliptin—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00308	0.00365	CcSEcCtD
Vildagliptin—Arthralgia—Lisinopril—systemic scleroderma	0.00304	0.0036	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00302	0.00357	CcSEcCtD
Vildagliptin—Pancreatitis—Prednisone—systemic scleroderma	0.00298	0.00353	CcSEcCtD
Vildagliptin—Asthenia—Captopril—systemic scleroderma	0.00295	0.00349	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00295	0.00349	CcSEcCtD
Vildagliptin—Headache—Mometasone—systemic scleroderma	0.00293	0.00347	CcSEcCtD
Vildagliptin—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00293	0.00347	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00293	0.00346	CcSEcCtD
Vildagliptin—Fatigue—Leflunomide—systemic scleroderma	0.00292	0.00346	CcSEcCtD
Vildagliptin—Oedema—Lisinopril—systemic scleroderma	0.00291	0.00345	CcSEcCtD
Vildagliptin—Constipation—Leflunomide—systemic scleroderma	0.0029	0.00343	CcSEcCtD
Vildagliptin—Infection—Lisinopril—systemic scleroderma	0.00289	0.00343	CcSEcCtD
Vildagliptin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00286	0.00338	CcSEcCtD
Vildagliptin—Skin disorder—Lisinopril—systemic scleroderma	0.00283	0.00335	CcSEcCtD
Vildagliptin—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00282	0.00333	CcSEcCtD
Vildagliptin—Diarrhoea—Captopril—systemic scleroderma	0.00281	0.00333	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00279	0.00331	CcSEcCtD
Vildagliptin—Fatigue—Mycophenolic acid—systemic scleroderma	0.00279	0.0033	CcSEcCtD
Vildagliptin—Nausea—Mometasone—systemic scleroderma	0.00278	0.00329	CcSEcCtD
Vildagliptin—Weight increased—Prednisone—systemic scleroderma	0.00277	0.00328	CcSEcCtD
Vildagliptin—Constipation—Mycophenolic acid—systemic scleroderma	0.00277	0.00327	CcSEcCtD
Vildagliptin—Dizziness—Captopril—systemic scleroderma	0.00272	0.00322	CcSEcCtD
Vildagliptin—Liver function test abnormal—Methotrexate—systemic scleroderma	0.00272	0.00321	CcSEcCtD
Vildagliptin—Urticaria—Leflunomide—systemic scleroderma	0.00269	0.00319	CcSEcCtD
Vildagliptin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00266	0.00315	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00265	0.00314	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00264	0.00313	CcSEcCtD
Vildagliptin—Headache—Captopril—systemic scleroderma	0.00258	0.00305	CcSEcCtD
Vildagliptin—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00255	0.00302	CcSEcCtD
Vildagliptin—Infection—Mycophenolate mofetil—systemic scleroderma	0.00254	0.003	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00251	0.00298	CcSEcCtD
Vildagliptin—Fatigue—Lisinopril—systemic scleroderma	0.00251	0.00297	CcSEcCtD
Vildagliptin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.0025	0.00296	CcSEcCtD
Vildagliptin—Pancreatitis—Methotrexate—systemic scleroderma	0.00249	0.00295	CcSEcCtD
Vildagliptin—Constipation—Lisinopril—systemic scleroderma	0.00249	0.00295	CcSEcCtD
Vildagliptin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00248	0.00293	CcSEcCtD
Vildagliptin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00247	0.00292	CcSEcCtD
Vildagliptin—Diarrhoea—Azathioprine—systemic scleroderma	0.00246	0.00291	CcSEcCtD
Vildagliptin—Nausea—Captopril—systemic scleroderma	0.00244	0.00289	CcSEcCtD
Vildagliptin—Asthenia—Leflunomide—systemic scleroderma	0.00243	0.00288	CcSEcCtD
Vildagliptin—Connective tissue disorder—Prednisone—systemic scleroderma	0.00239	0.00283	CcSEcCtD
Vildagliptin—Dizziness—Azathioprine—systemic scleroderma	0.00237	0.00281	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00236	0.0028	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00233	0.00275	CcSEcCtD
Vildagliptin—Asthenia—Mycophenolic acid—systemic scleroderma	0.00232	0.00275	CcSEcCtD
Vildagliptin—Diarrhoea—Leflunomide—systemic scleroderma	0.00232	0.00275	CcSEcCtD
Vildagliptin—Urticaria—Lisinopril—systemic scleroderma	0.00231	0.00274	CcSEcCtD
Vildagliptin—Infestation NOS—Methotrexate—systemic scleroderma	0.00227	0.00268	CcSEcCtD
Vildagliptin—Infestation—Methotrexate—systemic scleroderma	0.00227	0.00268	CcSEcCtD
Vildagliptin—Headache—Azathioprine—systemic scleroderma	0.00225	0.00266	CcSEcCtD
Vildagliptin—Dizziness—Leflunomide—systemic scleroderma	0.00224	0.00265	CcSEcCtD
Vildagliptin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00221	0.00262	CcSEcCtD
Vildagliptin—Angiopathy—Prednisone—systemic scleroderma	0.00221	0.00262	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.0022	0.00261	CcSEcCtD
Vildagliptin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00218	0.00258	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.00214	0.00254	CcSEcCtD
Vildagliptin—Dizziness—Mycophenolic acid—systemic scleroderma	0.00214	0.00253	CcSEcCtD
Vildagliptin—Nausea—Azathioprine—systemic scleroderma	0.00213	0.00252	CcSEcCtD
Vildagliptin—Headache—Leflunomide—systemic scleroderma	0.00212	0.00251	CcSEcCtD
Vildagliptin—Malnutrition—Prednisone—systemic scleroderma	0.00212	0.00251	CcSEcCtD
Vildagliptin—Asthenia—Lisinopril—systemic scleroderma	0.00209	0.00247	CcSEcCtD
Vildagliptin—Hepatitis—Methotrexate—systemic scleroderma	0.00204	0.00241	CcSEcCtD
Vildagliptin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00203	0.0024	CcSEcCtD
Vildagliptin—Headache—Mycophenolic acid—systemic scleroderma	0.00203	0.0024	CcSEcCtD
Vildagliptin—Nausea—Leflunomide—systemic scleroderma	0.00201	0.00238	CcSEcCtD
Vildagliptin—Diarrhoea—Lisinopril—systemic scleroderma	0.00199	0.00236	CcSEcCtD
Vildagliptin—Angioedema—Prednisone—systemic scleroderma	0.00194	0.00229	CcSEcCtD
Vildagliptin—Dizziness—Lisinopril—systemic scleroderma	0.00193	0.00228	CcSEcCtD
Vildagliptin—Nausea—Mycophenolic acid—systemic scleroderma	0.00192	0.00227	CcSEcCtD
Vildagliptin—Angiopathy—Methotrexate—systemic scleroderma	0.00185	0.00219	CcSEcCtD
Vildagliptin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00183	0.00217	CcSEcCtD
Vildagliptin—Chills—Methotrexate—systemic scleroderma	0.00183	0.00216	CcSEcCtD
Vildagliptin—Headache—Lisinopril—systemic scleroderma	0.00182	0.00216	CcSEcCtD
Vildagliptin—Arthralgia—Prednisone—systemic scleroderma	0.0018	0.00214	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00179	0.00212	CcSEcCtD
Vildagliptin—Malnutrition—Methotrexate—systemic scleroderma	0.00177	0.0021	CcSEcCtD
Vildagliptin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00175	0.00207	CcSEcCtD
Vildagliptin—Nausea—Lisinopril—systemic scleroderma	0.00173	0.00205	CcSEcCtD
Vildagliptin—Oedema—Prednisone—systemic scleroderma	0.00173	0.00205	CcSEcCtD
Vildagliptin—Infection—Prednisone—systemic scleroderma	0.00172	0.00203	CcSEcCtD
Vildagliptin—Nervous system disorder—Prednisone—systemic scleroderma	0.0017	0.00201	CcSEcCtD
Vildagliptin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00169	0.002	CcSEcCtD
Vildagliptin—Skin disorder—Prednisone—systemic scleroderma	0.00168	0.00199	CcSEcCtD
Vildagliptin—Hyperhidrosis—Prednisone—systemic scleroderma	0.00167	0.00198	CcSEcCtD
Vildagliptin—Headache—Mycophenolate mofetil—systemic scleroderma	0.0016	0.00189	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.00158	0.00187	CcSEcCtD
Vildagliptin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00152	0.00179	CcSEcCtD
Vildagliptin—Arthralgia—Methotrexate—systemic scleroderma	0.00151	0.00179	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.0015	0.00177	CcSEcCtD
Vildagliptin—Fatigue—Prednisone—systemic scleroderma	0.00149	0.00177	CcSEcCtD
Vildagliptin—Constipation—Prednisone—systemic scleroderma	0.00148	0.00175	CcSEcCtD
Vildagliptin—Infection—Methotrexate—systemic scleroderma	0.00144	0.0017	CcSEcCtD
Vildagliptin—Nervous system disorder—Methotrexate—systemic scleroderma	0.00142	0.00168	CcSEcCtD
Vildagliptin—Skin disorder—Methotrexate—systemic scleroderma	0.0014	0.00166	CcSEcCtD
Vildagliptin—Hyperhidrosis—Methotrexate—systemic scleroderma	0.0014	0.00165	CcSEcCtD
Vildagliptin—Urticaria—Prednisone—systemic scleroderma	0.00137	0.00163	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00132	0.00156	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00125	0.00148	CcSEcCtD
Vildagliptin—Fatigue—Methotrexate—systemic scleroderma	0.00125	0.00148	CcSEcCtD
Vildagliptin—Asthenia—Prednisone—systemic scleroderma	0.00124	0.00147	CcSEcCtD
Vildagliptin—Diarrhoea—Prednisone—systemic scleroderma	0.00118	0.0014	CcSEcCtD
Vildagliptin—Urticaria—Methotrexate—systemic scleroderma	0.00115	0.00136	CcSEcCtD
Vildagliptin—Dizziness—Prednisone—systemic scleroderma	0.00114	0.00135	CcSEcCtD
Vildagliptin—Headache—Prednisone—systemic scleroderma	0.00108	0.00128	CcSEcCtD
Vildagliptin—Asthenia—Methotrexate—systemic scleroderma	0.00104	0.00123	CcSEcCtD
Vildagliptin—Nausea—Prednisone—systemic scleroderma	0.00103	0.00122	CcSEcCtD
Vildagliptin—Diarrhoea—Methotrexate—systemic scleroderma	0.000989	0.00117	CcSEcCtD
Vildagliptin—Dizziness—Methotrexate—systemic scleroderma	0.000956	0.00113	CcSEcCtD
Vildagliptin—Headache—Methotrexate—systemic scleroderma	0.000906	0.00107	CcSEcCtD
Vildagliptin—Nausea—Methotrexate—systemic scleroderma	0.000859	0.00102	CcSEcCtD
